About Kinesin light chain 3
Kinesin light chain 3 (KLC3) is a protein
from Homo sapiens identified by UniProt accession
Q6P597, 504 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Kinesin light chain 3 |
| UniProt accession | Q6P597 |
| Gene | KLC3 |
| Organism | Homo sapiens |
| Length | 504 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- monocyte count · score 0.24
- ovarian cancer · score 0.18
- breast adenocarcinoma · score 0.18
- Xeroderma pigmentosum complementation group D · score 0.18
- leukocyte count · score 0.15
- glioblastoma multiforme · score 0.15
- neutrophil count · score 0.13
- xeroderma pigmentosum · score 0.12
- medulloblastoma · score 0.10
- isolated asymptomatic elevation of creatine phosphokinase · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6P597-F1 | alphafold | PREDICTED | 74.86 | — |
Amino-acid sequence (504 residues)
MSVQVAAPGS AGLGPERLSP EELVRQTRQV VQGLEALRAE HHGLAGHLAE ALAGQGPAAG LEMLEEKQQV VSHSLEAIEL GLGEAQVLLA LSAHVGALEA EKQRLRSQAR RLAQENVWLR EELEETQRRL RASEESVAQL EEEKRHLEFL GQLRQYDPPA ESQQSESPPR RDSLASLFPS EEEERKGPEA AGAAAAQQGG YEIPARLRTL HNLVIQYAGQ GRYEVAVPLC RQALEDLERS SGHCHPDVAT MLNILALVYR DQNKYKEATD LLHDALQIRE QTLGPEHPAV AATLNNLAVL YGKRGRYREA EPLCQRALEI REKVLGADHP DVAKQLNNLA LLCQNQGKFE DVERHYARAL SIYEALGGPH DPNVAKTKNN LASAYLKQNK YQQAEELYKE ILHKEDLPAP LGAPNTGTAG DAEQALRRSS SLSKIRESIR RGSEKLVSRL RGEAAAGAAG MKRAMSLNTL NVDAPRAPGT QFPSWHLDKA PRTLSASTQD LSPH
Explore Kinesin light chain 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets